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ABSTRACT
Introduction: This study is a retrospective case
series to evaluate the outcomes and
complications of Baerveldt glaucoma implant
surgery (BGI) in patients without prior cataract
or incisional glaucoma surgery.
Methods: Patients who underwent 350-mm2
BGI through the Glaucoma Service of the
University of Illinois at Chicago between 2010
and 2015 were included in this study. Outcome
measures included age, sex, ethnicity, operated
eye, preoperative diagnosis, preoperative, and
sequential postoperative intraocular pressure
(IOP), visual acuity, glaucoma medications, and
postoperative complication and interventions.
Statistical analyses were performed using the
two-sided Student t test for continuous variables.
Results: Thirty-seven patients were studied.
IOP was consistently and statistically
significantly lower at 3 months (17.4 ± 6.4,
p = 3 9 10-7), 6 months (13.9 ± 5.1, p = 2 9
10-11), 1 year (12.2 ± 4.0, p = 9 9 10-10), and
2 years (14.6 ± 3.3, p = 0.0004) postoperatively
compared to IOP at baseline (27.5 ± 8.1). Fewer
glaucoma medications were used at 3 months
(2.8 ± 1.3, p = 0.04), 6 months (2.6 ± 1.2,
p = 0.02), 1 year (2.7 ± 1.7, p = 0.04), and
2 years (2.0 ± 1.2, p = 0.03) postoperatively
compared to baseline (3.4 ± 1.1). A total of six
cases (16%) had failure. A total of five patients
(15%) had postoperative complications. Mean
Snellen visual acuity was not statistically
different at 6 months (0.5 ± 0.6, p = 0.88) or
1 year (0.4 ± 0.4, p = 0.57) postoperatively from
baseline (0.5 ± 0.6).
Conclusions: Primary BGI is effective at
reducing IOP and the medication burden in
patients suffering glaucomatous optic
neuropathy. Further randomized prospective
studies are needed to compare various
procedures in the primary surgical
management of patients with uncontrolled
glaucoma.
Funding: This study was funded by an
unrestricted grant from Research to Prevent
Blindness.
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INTRODUCTION
Incisional glaucoma surgery is generally
indicated when medical therapy and laser
treatments fail to control intraocular pressure
(IOP) adequately. Trabeculectomy remains the
most commonly performed incisional
glaucoma surgery worldwide [1]. However,
recent surveys of the American Glaucoma
Society have shown an increase in the
proportion of practitioners using tube shunts
and a decrease in the popularity of
trabeculectomy [2]. Medicare data has also
demonstrated an increase in the number of
tube shunts with a decline in trabeculectomies
from 1995 to 2004 [3]. The Tube Versus
Trabeculectomy study demonstrated that
Baerveldt glaucoma implant (BGI; Advanced
Medical Optics, Santa Ana, CA, USA) surgery
had a higher success rate compared to
trabeculectomy, with fewer postoperative
complications in patients with prior
glaucoma or cataract surgery. In a recent
retrospective study, Panarelli et al. [4]. have
shown similar rates of surgical success and
post-operative complications in patients
undergoing trabeculectomy with mitomycin
C (MMC) and in those undergoing Baerveldt
glaucoma implant surgery during a 3-year
follow-up.
This retrospective case series evaluated the
outcomes and complications of Baerveldt
glaucoma implant surgery in patients
without prior cataract or incisional glaucoma
surgery.
METHODS
The Institutional Review Board of the
University of Illinois at Chicago Human
Subject Research Committee approved this
study. Informed consent was obtained from all
patients for being included in the study.
Patients who underwent 350-mm2 Baerveldt
glaucoma implant surgery through the
Glaucoma Service of the University of Illinois
at Chicago between 2010 and 2015 were
identified using Current Procedural
Terminology codes. Patients were excluded if
they were younger than 18 or older than
85 years of age, had undergone prior incisional
ocular surgery, had an IOP less than 18 mmHg
immediately before the surgery, or had fewer
than 6 months of postoperative follow-up.
Exclusion criteria also included preoperative
no light perception vision; pregnant or
nursing women; active iris neovascularization
or proliferative retinopathy; iridocorneal
endothelial syndrome; and epithelial or fibrous
down-growth. Information obtained from the
medical records of each patient included age,
sex, ethnicity, operated eye, preoperative
diagnosis, preoperative and sequential
postoperative IOP, visual acuity (VA),
glaucoma medications, and postoperative
complication and interventions.
Consistent with prior reports, we defined
failure was defined as IOP [21 mmHg or less
than 20% reduction below baseline on two
consecutive follow-up visits after 3 months, IOP
B5 mmHg on two consecutive follow-up visits
after 3 months, reoperation for glaucoma, or
loss of light perception vision [1, 4]. All eyes
that had not failed by the above criteria and
were not on supplemental medical therapy were
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considered complete success. Eyes were
considered a qualified success if they did not
meet failure criteria, yet required supplemental
medical therapy. Reoperation for glaucoma was
defined as additional surgery requiring a return
to the operating room. Laser cyclodestructive
therapy was considered a reoperation for
glaucoma and therefore a failure. A vitreous
tap with injection of intravitreal antibiotics was
considered a reoperation for a surgical
complication and, therefore, a failure.
Interventions performed at the slit-lamp, such
as needling procedures or reformation of the
anterior chamber, were not considered
reoperations for glaucoma or a complication
and, therefore, not classified as failures.
Persistent diplopia and corneal edema, as well
as dysesthesia, were defined as the postoperative
development of these complications and their
continued presence at the 6-month follow-up
visit or after. Eyes that tested Seidel positive
within the first month of follow-up were
classified as wound leaks, and those occurring
after 1 month were categorized as bleb leaks.
Patients who underwent additional glaucoma
surgery were censored from analysis of
complications after the reoperation for
glaucoma. Cataracts were considered to have
progressed if there was loss of 2 or more lines of
Snellen VA attributable to cataract, or if cataract
surgery was performed.
Statistical analyses were performed using the
two-sided Student t-test for continuous
variables. Snellen VA measurements were
converted to logarithm of the minimal angle
of resolution (logMAR) equivalents for the
purpose of the data analysis. A p value of 0.05
or less was considered statistically significant in
our analyses. Failed eyes were excluded from
further analyses of IOP, VA, or glaucoma
medications beyond the time-point of failure.
Compliance with Ethics Guidelines
The Institutional Review Board of the
University of Illinois at Chicago Human
Subject Research Committee approved this
study. Informed consent was obtained from all
patients for being included in the study.
RESULTS
Baseline characteristics of study patients are
presented in Table 1. A total of 37 patients met
the eligibility criteria for the study. The
majority of patients were male (62%) and
most patients were African American (51%).
The most common diagnosis was primary
open-angle glaucoma (POAG, 73%).
Baseline and follow-up IOP measurements
are shown in Table 2 and Fig. 1. The number of
patients who were censored at 3 months,
6 months, and 1 year was 2 at each time point.
Additional reduction in the number of patients
at follow-up time points was the result of missed
visits. IOP was consistently and statistically
significantly lower at each follow-up time
point compared to IOP at baseline.
The number of glaucoma medications at
baseline and follow-up is reported in Table 2
and Fig. 2. Fewer glaucoma medications were
used at every follow-up time point compared to
baseline.
A total of six cases (16%) had failure. The
most common cause of failure was inadequate
IOP reduction in four patients (10%), followed
by persistent hypotony in one patient (2%) and
reoperation for glaucoma in another patient
(2%). One patient underwent shunt revision for
hypotony at postoperative month 3 with
successful outcome. Another patient
underwent cyclophotocoagulation at
postoperative year 1 for inadequate IOP
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reduction with successful outcome. The
remaining 31 cases of successful outcome
included three cases (7%) of complete success
and 28 cases (75%) of qualified success.
Postoperative complications and
interventions are shown in Table 3. A total of
five patients (15%) experienced postoperative
complications. One patient required
reoperation to treat the complication. One
additional patient required reforming of
anterior chamber with viscoelastic due to
shallow anterior chamber noted
postoperatively. The treatment outcome for
this patient was considered a qualified success.
Mean Snellen VA ± standard deviation at
baseline, 6 months postoperatively, and 1 year
postoperatively were 0.5 ± 0.6, 0.5 ± 0.6, and
0.4 ± 0.4, respectively. Mean Snellen VA was
not statistically different at 6 months or 1 year
postoperatively from baseline (p = 0.88 and
Table 1 Baseline characteristics of patients
Age, years







African American 19 (51)
Hispanic 11 (29)
Other 0 (0)
Hypertension, no. (%) 20 (54)
Diabetes mellitus, no. (%) 12 (32)












logMAR mean ± SD 0.5 ± 0.6
IOP, mmHg
Mean ± SD 27.5 ± 8.1
Range 18–55
Glaucoma medications, mean ± SD
PGA 35 (95)
BB 33 (89)
Topical CAi 28 (76)
Table 1 continued
Alpha2 agonist 29 (78)
Oral CAi 12 (32)
Miotics 1 (3)
Others 0





SD standard deviation, POAG primary open angle
glaucoma, CACG chronic angle closure glaucoma, PXFG
pseudoexfoliation glaucoma, PG pigmentary glaucoma,
Misc chronic angle closure glaucoma, neovascular
glaucoma, etc., CF counting ﬁngers, logMAR logarithm
of the minimum angle of resolution, PGA prostaglandin
analogues, BB beta blockers, CAi carbonic anhydrase
inhibitors, SLT selective laser trabeculoplasty, ALT argon
laser trabeculoplasty, LPI laser peripheral iridotomy
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p = 0.57, respectively). A total of four patients
(10%) had progression of cataract.
DISCUSSION
This retrospective case series investigated the
outcomes of primary Baerveldt glaucoma
implant surgery in patients with medically
uncontrolled glaucoma without prior cataract
or incisional glaucoma surgery and yielded
three key findings. First, primary Baerveldt
glaucoma implant surgery resulted in a
significant IOP reduction by 6 months and
that reduction persisted at 1 year following
surgery. Second, patients required significantly
fewer glaucoma medications at 3 months
following shunt implantation. Third, primary
Baerveldt shunt implantation is safe with
respect to visual acuity and postoperative
complications.
For decades, trabeculectomy has been the
incisional surgery of choice for the modern
management of uncontrolled glaucoma [5–7].
Table 2 Intraocular pressure and medical therapy for
patients at baseline and follow-up
p value
Baseline
IOP (mmHg) 27.5 ± 8.1
No. of glaucoma medications 3.4 ± 1.1
No. of patients 37
3 Months
IOP (mmHg) 17.4 ± 6.4 3 9 10-7
No. of glaucoma medications 2.8 ± 1.3 0.04
No. of patients 36
6 Months
IOP (mmHg) 13.9 ± 5.1 2 9 10-11
No. of glaucoma medications 2.6 ± 1.2 0.02
No. of patients 36
1 Year
IOP (mmHg) 12.2 ± 4.0 9 9 10-10
No. of glaucoma medications 2.7 ± 1.7 0.04
No. of patients 22
2 Years
IOP (mmHg) 14.6 ± 3.3 0.004
No. of glaucoma medications 2.0 ± 1.2 0.03
No. of patients 5
Data is presented as mean ± standard deviation
IOP intraocular pressure
Fig. 1 Mean intraocular pressure at baseline and follow-up
time points. Error bars indicate the 95% conﬁdence
interval
Fig. 2 The number of glaucoma medications at baseline
and follow-up time points. Error bars indicate the 95%
conﬁdence interval
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Trabeculectomy has shown to be effective at
reducing IOP and reducing the risk of
progressive glaucomatous visual field loss
[8, 9]. Antimetabolites such as MMC or 5-FU
augment that IOP reduction and can enhance
the success rate of trabeculectomy surgery;
[10, 11] indeed, antimetabolite therapy is
routinely combined with trabeculectomy
among most glaucoma practitioners [12].
However, adjunctive antimetabolite therapy is
associated with significant complications,
including bleb leaks, hypotony, and cataract
[10]. The rate of wound leaks after
trabeculectomy with an adjunctive antifibrotic
agent has been reported as high as 32% when
Seidel testing is rigorously performed at each
clinic, leading some practitioners to investigate
other surgical options.
Historically, aqueous shunt implant surgery
has been reserved for patients with advanced
glaucoma who previously had failed
trabeculectomy or in cases with a poor
prognosis with filtering surgery, such as active
neovascular glaucoma, aphakic/pseudophakic
glaucoma with severe uveitis, or in patients
with extensive perilimbal conjunctival scarring
[13–16]. With the known complications of
trabeculectomy with adjuvant antimetabolite
therapy and the growing improvement in
surgical techniques and physician comfort
with aqueous shunt implants, there has been
renewed interest in expanding the role of
aqueous shunt implantation [3, 17, 18]. The
Tube Versus Trabeculectomy (TVT) study
compared the safety and efficacy of
non-valved tube shunt surgery with
trabeculectomy with MMC in patients who
had previously undergone cataract extraction
with IOL implantation and/or failed filtering
surgery. In this randomized prospective study,
tube shunt surgery was more likely to maintain
IOP control and avoid persistent hypotony or
reoperation for glaucoma than trabeculectomy
with MMC during 1 year of follow-up [18].
Although there was less need for supplemental
medical therapy after trabeculectomy at 1 year,
vision loss occurred at a similar rate after both
procedures [18]. At 5 years, the rates of late
postoperative complications and reoperation
for complications were similar. Overall rate of
complications was significantly higher in the
trabeculectomy group compared with the tube
group: in particular, bleb leaks and dysethesia
occurred with significantly greater frequency in
the trabeculectomy group. In contrast, no
postoperative complications were significantly
more common in the tube group [16]. While a
prospective study is underway comparing
primary tube vs. trabeculectomy, the study
suggests a favorable role in expanding the role
of BGI.
Recently, outcomes were reported
comparing the safety and efficacy of Baerveldt
glaucoma implant surgery and trabeculectomy
with MMC in patients who had not undergone
prior incisional surgery [4]. At 6 months of
follow-up, Baerveldt glaucoma implant surgery




Shallow anterior chamber 1 (3%) Reforming by
Healon
Hyphema 2 (5%) Spontaneous
resolution
Late postoperative complications
Chronic iritis 1 (3%) Failure
Persistent choroidal and
RRD
1 (3%) PPV and RRD
repair
Total 5 (15%)
RRD rhegmatogenous retinal detachment, PPV pars plana
vitrectomy
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produced a 50% decrease in IOP whereas
trabeculectomy with MMC produced a 62%
reduction, a result similar to earlier reports in
the literature [4, 19–21]. Those IOP reductions
were stable at 5 years in both groups, suggesting
that the IOP at 6 months may be a good
predictor of long-term IOP reduction. In the
current study examining the efficacy of BGI as a
primary glaucoma surgery, IOP was reduced
from baseline by 49.5% at 6 months and 55.6%
at 1 year. As in the study by Panarelli et al. [4],
IOP was reduced by 6 months and that
reduction was stable at 1 year. These results are
similar to those seen at similar postoperative
time points in the tube group of the TVT study,
where IOP was reduced from baseline by 50.1%
at 1 year following surgery in patients with prior
incisional ocular surgery [16].
Patients in the current study required
significantly fewer glaucoma medications at all
time points following surgery. The mean
number of glaucoma medications was
2.6 ± 1.2 at 6 months and 2.7 ± 1.7 at 1 year,
somewhat higher than the mean number
(1.8 ± 1.5 and 1.9 ± 1.5, respectively) reported
in the Baerveldt group of the study by Panarelli
et al. [4], as well as that of the tube group of TVT
at 1.3 ± 1.3 (at 1 year) [16]. Possibly medication
non-adherence, a well-known challenge in
glaucoma management [22, 23], may have
accounted for this difference.
There were a total of five postoperative
complications in this study, including anterior
chamber shallowing, hyphema, chronic iritis,
persistent choroidal effusion, and
rhegmatogenous retinal detachment. The
overall rate of postoperative complications was
15%, similar to that seen in a recent study of
patients undergoing primary BGI [4]. While that
study included persistent corneal edema, bleb
leak, and persistent diplopia as postoperative
complications in the BGI group, in this study
there were no patients with those
complications. Although variability among
practitioners may account for this difference,
the current study was also not adequately
powered to detect relatively rare complications
of BGI surgery [15, 24]. Interestingly, in both
the current study and that by Panarelli et al.
[4]., the overall complication rates (15% and
20%, respectively) were lower than the 34% rate
observed in the tube group of the TVT study
[25].
Prior studies have indicated that
postoperative visual acuity significantly
decreased following BGI [4, 25]. In patients
with no prior incisional ocular surgery, Snellen
visual acuity decreased by more than two lines
in 33% of patients following BGI at 3 years [4],
similar to that reported for the 39% of patients
without complications and the 51% of patients
with complications who experienced decreased
visual acuity in the tube group of TVT at 5 years
[25]. In the current study, mean visual acuity
was not statistically different at 6 months or
1 year postoperatively from baseline, although a
total of four patients did have progression of
cataract. Given that results were analyzed at
1 year following BGI in the current study,
further follow-up will be required to assess the
consistency of these visual acuity outcomes
with other reports. Another factor that
potentially contributed to unchanged visual
acuity was exclusion of failure cases from
visual acuity analysis beyond the time point of
failure.
This study has several limitations. Like all
retrospective studies, no standard protocol was
used to collect data at the time of follow-up
visits, which may have led to an
underestimation of adverse events.
Postoperative interventions and additional
medications were left to the discretion of the
surgeon, and no standardized protocols were
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used for postoperative management. The study
did not have adequate power to detect rare
complications of BGI surgery such as corneal
edema or diplopia [4]. Post-operative follow-up
was limited to 1 year following surgery, so
understanding the long-term effectiveness and
complications of BGI requires further inquiry.
This study also had specific inclusion criteria
and only examined outcomes in patients who
had undergone surgery with the 350 mm2
Baerveldt glaucoma implant, so it may be
difficult to generalize the results to valved tube
shunts (e.g. Ahmed valved implant) or other
non-valved devices. Finally, the ideal measure
of success in any glaucoma therapy is the
prevention of further optic nerve damage and
visual field loss. While this study focused on
lowering IOP as the primary goal of therapy
given its well-known role in delaying visual field
loss and optic disc progression [26], further
investigation is needed to assess the particular
effectiveness of BGI surgery on preventing
glaucomatous nerve damage compared to
other surgical procedures [9].
In summary, this study will help provide
evidence-based information that will assist in
surgical decision making for patients requiring a
primary procedure to manage glaucoma.
Primary BGI is effective at reducing IOP at
6 months, significantly decreases the
medication burden, and is associated with
relatively similar post-operative and visual
acuity complications at 1 year compared to
results seen in other studies, regardless of prior
incisional ocular surgery [4, 25]. The current
study adds substantial evidence that primary
aqueous shunt implants in general can
significantly lower IOP in patients with
uncontrolled glaucoma and no prior incisional
ocular surgery [27, 28]. While further
randomized prospective studies are needed to
establish definitively the comparative
effectiveness of various procedures in the
primary surgical management of patients with
uncontrolled glaucoma, the current study
supports an ever-expanding role for BGI.
While the risks and benefits of any surgical
option must be weighed with respect to the
individual characteristics of the patient’s
disease, this study underscores that BGI is a
viable alternative for the primary surgical
management of uncontrolled glaucoma.
CONCLUSIONS
Primary BGI significantly reduces IOP and the
medication burden in patients suffering
glaucomatous optic neuropathy. Further
randomized prospective studies are needed to
compare various procedures in the primary
surgical management of patients with
uncontrolled glaucoma.
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